Skip to content
Inciteful Med

Symptom Management & Current Treatments

Last updated:

While there is no cure for myotonic dystrophy, most symptoms are manageable. Treatment focuses on improving daily life through physical therapy, respiratory support like BiPAP for sleepiness, medications for muscle stiffness, and supportive care to manage digestive and mobility issues.

Key Takeaways

  • • Practical daily habits, such as keeping hands warm, and medications like mexiletine can help manage muscle stiffness (myotonia).
  • • Moderate aerobic exercise is beneficial, but eccentric exercises that lengthen muscles under load should be avoided to prevent excessive muscle damage.
  • • Excessive daytime sleepiness is common and should be evaluated for nighttime breathing issues before doctors prescribe stimulant medications.
  • • Digestive issues like trouble swallowing and slow motility can be managed through dietary adjustments, swallowing studies, and laxatives.
  • • Early integration of palliative care focuses on supportive symptom management to improve daily functioning and overall well-being.

While there is currently no cure for Myotonic Dystrophy, many of the symptoms that affect your daily life are highly manageable. The goal of treatment is to improve your quality of life, maintain your independence, and prevent complications [1].

Managing Muscle Stiffness (Myotonia)

Myotonia is the “sticky” feeling in your muscles.

  • Everyday Coping Strategies: Before turning to medication, many patients find relief through practical daily habits. These include keeping your hands warm (wearing gloves in cold weather or air conditioning), avoiding sudden, forceful grips (like tightly grabbing a steering wheel or a heavy jar), and using adaptive, wide-grip utensils for eating and writing [2].
  • Mexiletine: This is the most common medication used for myotonia [3]. However, because it is also a heart rhythm drug, your doctor must perform a thorough cardiac evaluation (including an EKG and often a 24-hour Holter monitor) before you start taking it to ensure it is safe for your heart [4][5].
  • Alternatives: If mexiletine is not safe for your heart, your doctor may consider alternatives like lamotrigine [6].

Managing Muscle Weakness and Mobility

Physical therapy (PT) and occupational therapy (OT) are the cornerstones of managing muscle weakness.

  • Exercise: Moderate aerobic exercise (like walking or swimming) and light resistance training are generally safe and can improve your strength and mitochondrial health [7][8].
  • A Note on Intensity: While exercise is beneficial, it is important to avoid “eccentric” exercises—movements that focus on the lengthening of a muscle under load, such as lowering heavy boxes from a shelf or repeatedly walking down steep stairs [9]. These movements cause micro-tears in the muscle fibers that your body cannot easily repair, leading to excessive muscle damage [9].
  • Assistive Devices: Tools like Ankle-Foot Orthotics (AFOs) can help with “foot drop,” preventing trips and falls, which are a major risk for both DM1 and DM2 patients [10].

Managing Fatigue and Sleepiness

Excessive daytime sleepiness (EDS) is one of the most common “hidden” symptoms. It is often caused by the brain’s sleep-wake signals being disrupted [11].

  • Rule Out Breathing First: Before prescribing stimulants (like modafinil), your doctor must ensure your sleepiness isn’t caused by poor breathing at night (nocturnal hypoventilation) [11].
  • Breathing Support: If a sleep study shows you aren’t breathing deeply enough at night, a Non-Invasive Ventilation (NIV) machine (like a BiPAP) can dramatically improve your daytime energy and long-term health [12].

Managing Digestive Health

The muscles of the gut are often affected in Myotonic Dystrophy, leading to dysmotility (food moving too slowly) [13].

  • Common Issues: Many patients experience trouble swallowing (dysphagia), frequent bloating, or chronic constipation [14][13].
  • Management: Strategies include eating smaller, more frequent meals, staying hydrated, and using gentle laxatives if recommended [15]. If you have trouble swallowing, a videofluoroscopic swallow study (VFSS) can help determine which foods are safest for you [16].

The Role of Palliative Care

In the context of Myotonic Dystrophy, palliative care does not mean end-of-life care or hospice. Instead, it is supportive care focused on relieving symptoms and reducing the “burden” of the disease [17]. This includes managing pain, addressing apathy or depression, and coordinating the many different specialists on your team [1][18]. Integrating supportive care early helps you focus on what matters most: your daily functioning and well-being [17].

Frequently Asked Questions

How can I manage muscle stiffness and myotonia?
Everyday strategies like keeping your hands warm in cold weather and using adaptive, wide-grip utensils can help. If medication is needed, doctors often prescribe mexiletine, though a thorough heart evaluation is required before starting it.
Why am I experiencing excessive daytime sleepiness with myotonic dystrophy?
Excessive daytime sleepiness is common and may be caused by disrupted sleep-wake signals in the brain. However, your doctor should first perform a sleep study to ensure your fatigue isn't actually caused by shallow breathing at night.
What types of exercise are safe for someone with myotonic dystrophy?
Moderate aerobic activities like walking or swimming and light resistance training are safe and can improve strength. However, you should avoid 'eccentric' exercises—like lowering heavy boxes or walking down steep stairs—because they cause muscle damage your body cannot easily repair.
How does myotonic dystrophy affect digestion and swallowing?
The muscles of the gut are often affected, causing food to move too slowly. This can lead to trouble swallowing, frequent bloating, and chronic constipation. Eating smaller, frequent meals and staying hydrated can help manage these symptoms.
Does palliative care mean end-of-life care for myotonic dystrophy?
No. For myotonic dystrophy, palliative care is simply supportive care. It focuses on relieving daily symptoms, managing pain, addressing depression, and coordinating your medical specialists so you can maintain the best possible quality of life.

Questions for Your Doctor

  • • Before starting mexiletine for my muscle stiffness, can we review my latest EKG and Holter monitor results to ensure it is safe for my heart?
  • • Is the daytime sleepiness I am feeling a 'central' brain issue or could it be caused by poor breathing at night? Can we schedule a sleep study to check?
  • • Can you refer me to a physical therapist who has experience with neuromuscular diseases like mine to help me design a safe exercise plan?
  • • Are there specific prokinetic medications or dietary changes you recommend for my bloating and constipation?
  • • How can we integrate 'supportive' or 'palliative' care into my routine to focus on my daily quality of life and energy levels?

Questions for You

  • • When I try to exercise, do I feel energized afterward, or do I experience extreme pain and weakness that lasts for days?
  • • Do I notice that my muscle 'stickiness' is worse in the cold or when I am stressed, and can I use gloves or adaptive tools to help?
  • • Am I having trouble swallowing certain foods, or do I find myself coughing frequently while eating?
  • • Do I have a medical alert card that I can show to a dentist or surgeon before any procedure involving sedation?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Health-related quality of life, pain, and fatigue in myotonic dystrophy type 2: a 13-year follow-up study.

    Damen MJ, Mul K, van Engelen BGM, et al.

    Disability and rehabilitation 2025; 1-8 doi:10.1080/09638288.2025.2571068.

    PMID: 41173243
  2. 2

    Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia.

    Locci S, Cardani R, Brunori P, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):5365-5368 doi:10.1007/s10072-021-05538-y.

    PMID: 34386887
  3. 3

    Evaluation of professional practices in the use of mexiletine for the management of childhood myotonia in French pediatric neuromuscular centers (MEXI-PEDI survey).

    Barrière S, Manel V, Barnerias C, et al.

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2025; (32(2)):107-113 doi:10.1016/j.arcped.2024.10.009.

    PMID: 39875220
  4. 4

    Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic dystrophy type 1 over long-term follow-up.

    Vio R, Zorzi A, Bello L, et al.

    Heart rhythm 2020; (17(11)):1944-1950 doi:10.1016/j.hrthm.2020.05.043.

    PMID: 32525073
  5. 5

    Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.

    Wahbi K, Bassez G, Duchateau J, et al.

    Archives of cardiovascular diseases 2024; (117(6-7)):450-456 doi:10.1016/j.acvd.2024.03.001.

    PMID: 38677940
  6. 6

    Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial.

    Vivekanandam V, Skorupinska I, Jayaseelan DL, et al.

    The Lancet. Neurology 2024; (23(10)):1004-1012 doi:10.1016/S1474-4422(24)00320-X.

    PMID: 39304240
  7. 7

    Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.

    Manta A, Stouth DW, Xhuti D, et al.

    The Journal of physiology 2019; (597(5)):1361-1381 doi:10.1113/JP277123.

    PMID: 30628727
  8. 8

    Resistance Exercise Training Rescues Mitochondrial Dysfunction in Skeletal Muscle of Patients with Myotonic Dystrophy Type 1.

    Di Leo V, Lawless C, Roussel MP, et al.

    Journal of neuromuscular diseases 2023; (10(6)):1111-1126 doi:10.3233/JND-230099.

    PMID: 37638448
  9. 9

    What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review.

    Roussel MP, Morin M, Gagnon C, Duchesne E

    BMC musculoskeletal disorders 2019; (20(1)):101 doi:10.1186/s12891-019-2458-7.

    PMID: 30836978
  10. 10

    High incidence of falls in patients with myotonic dystrophy type 1 and 2: A prospective study.

    Berends J, Tieleman AA, Horlings CGC, et al.

    Neuromuscular disorders : NMD 2019; (29(10)):758-765 doi:10.1016/j.nmd.2019.08.012.

    PMID: 31540818
  11. 11

    Excessive daytime sleepiness in myotonic dystrophy: a narrative review.

    Hoxhaj D, Pascazio A, Maestri M, et al.

    Frontiers in neurology 2024; (15()):1389949 doi:10.3389/fneur.2024.1389949.

    PMID: 39011358
  12. 12

    Sleep-disordered breathing and effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with myotonic dystrophy type I.

    Spiesshoefer J, Runte M, Heidbreder A, et al.

    Neuromuscular disorders : NMD 2019; (29(4)):302-309 doi:10.1016/j.nmd.2019.02.006.

    PMID: 30898523
  13. 13

    High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

    Hilbert JE, Barohn RJ, Clemens PR, et al.

    Neurology 2017; (89(13)):1348-1354 doi:10.1212/WNL.0000000000004420.

    PMID: 28855409
  14. 14

    Impact of gastrointestinal and urological symptoms in children with myotonic dystrophy type 1.

    Maagdenberg SJM, Klinkenberg S, Sophie van den Berg J, et al.

    Neuromuscular disorders : NMD 2024; (35()):1-7 doi:10.1016/j.nmd.2023.12.011.

    PMID: 38184901
  15. 15

    Diabetic Gastroparesis.

    Bharucha AE, Kudva YC, Prichard DO

    Endocrine reviews 2019; (40(5)):1318-1352 doi:10.1210/er.2018-00161.

    PMID: 31081877
  16. 16

    Adherence to Non-Invasive Ventilation in Steinert Disease: Clinical and Psychological Insights.

    Annunziata A, Simioli F, Polistina GE, et al.

    Brain sciences 2025; (15(9)) doi:10.3390/brainsci15090968.

    PMID: 41008328
  17. 17

    Myotonic dystrophy type 1: palliative care guidelines.

    Willis D, Willis T, Bassie C, et al.

    BMJ supportive & palliative care 2024; doi:10.1136/spcare-2023-004748.

    PMID: 38253488
  18. 18

    [Adult myotonic dystrophy type 1: an update].

    Rosado-Bartolomé A, Gutiérrez-Gutiérrez G, Prieto-Matos J

    Semergen 2020; (46(5)):355-362 doi:10.1016/j.semerg.2020.01.002.

    PMID: 32646725

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist or healthcare provider regarding specific symptom management and treatment plans for myotonic dystrophy.

Stay up to date

Get notified when new research about Myotonic dystrophy is published.

No spam. Unsubscribe anytime.